Literature DB >> 25938168

Do the aryl hydrocarbon receptor interacting protein variants (Q228K and Q307R) play a role in patients with familial and sporadic hormone-secreting pituitary adenomas?

Sema Yarman1, Yeliz Duvarci Ogret2, Fatma Savran Oguz2.   

Abstract

AIM: The aim of this study was to examine mutations in the aryl hydrocarbon receptor-interacting protein (AIP) gene by sequence analysis of exons 1-6 using leukocyte genomic DNA obtained from a cohort of familial isolated pituitary adenoma (FIPA) and apparent sporadic functional pituitary adenoma Turkish patients.
METHODS: Fourteen FIPA and 90 sporadic pituitary adenoma (somatotrophinoma, prolactinoma, and corticotrophinoma) patients, 1 sporadic gigantism case, and 70 healthy controls were included in the study.
RESULTS: We did not detect AIP mutations in patients with FIPAs or sporadic pituitary adenomas, including the gigantism case. Only two exonic homozygous missense single-nucleotide polymorphisms (rs641081 [Q228K] and rs4930195 [Q307R]) were identified in the AIP locus. Minor allele frequencies of the Q307R and Q228K variants were significantly higher in FIPA patients compared to controls. In addition, the minor allele frequency of the Q228K variant was significantly increased in patients with sporadic somatotrophinomas compared to controls, whereas the minor allele frequency of the Q307R variant was significantly increased in corticotrophinoma patients compared to controls. Conversely, the minor allele frequencies of Q228R and Q307R variants were similar between patients with prolactinomas and controls. No AIP gene mutation or variant was observed in the sporadic gigantism patient. These results suggest that Q228K and Q307R variants in the AIP gene might be involved in the genetic susceptibility to familial and sporadic pituitary adenomas (somatotrophinoma and corticotrophinoma) in the Turkish population.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25938168      PMCID: PMC4507083          DOI: 10.1089/gtmb.2014.0333

Source DB:  PubMed          Journal:  Genet Test Mol Biomarkers        ISSN: 1945-0257


  26 in total

1.  Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients.

Authors:  Laure Cazabat; Jérôme Bouligand; Sylvie Salenave; Michèle Bernier; Stephan Gaillard; Fabrice Parker; Jacques Young; Anne Guiochon-Mantel; Philippe Chanson
Journal:  J Clin Endocrinol Metab       Date:  2012-02-08       Impact factor: 5.958

2.  High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas.

Authors:  Maria A Tichomirowa; Anne Barlier; Adrian F Daly; Marie-Lise Jaffrain-Rea; Cristina Ronchi; Maria Yaneva; Jonathan D Urban; Patrick Petrossians; Atanaska Elenkova; Antoine Tabarin; Rachel Desailloud; Dominique Maiter; Thomas Schürmeyer; Renato Cozzi; Marily Theodoropoulou; Caroline Sievers; Ignacio Bernabeu; Luciana A Naves; Olivier Chabre; Carmen Fajardo Montañana; Vaclav Hana; Georges Halaby; Brigitte Delemer; José Ignacio Labarta Aizpún; Emmanuel Sonnet; Angel Ferrandez Longás; Marie-Thérèse Hagelstein; Philippe Caron; Günter K Stalla; Vincent Bours; Sabina Zacharieva; Anna Spada; Thierry Brue; Albert Beckers
Journal:  Eur J Endocrinol       Date:  2011-07-13       Impact factor: 6.664

3.  Pituitary adenoma predisposition caused by germline mutations in the AIP gene.

Authors:  Outi Vierimaa; Marianthi Georgitsi; Rainer Lehtonen; Pia Vahteristo; Antti Kokko; Anniina Raitila; Karoliina Tuppurainen; Tapani M L Ebeling; Pasi I Salmela; Ralf Paschke; Sadi Gündogdu; Ernesto De Menis; Markus J Mäkinen; Virpi Launonen; Auli Karhu; Lauri A Aaltonen
Journal:  Science       Date:  2006-05-26       Impact factor: 47.728

Review 4.  AIP and its interacting partners.

Authors:  Giampaolo Trivellin; Márta Korbonits
Journal:  J Endocrinol       Date:  2011-03-31       Impact factor: 4.286

5.  Familial acromegaly due to aryl hydrocarbon receptor-interacting protein (AIP) gene mutation in a Turkish cohort.

Authors:  Mutlu Niyazoglu; Muge Sayitoglu; Sinem Firtina; Esra Hatipoglu; Nurperi Gazioglu; Pinar Kadioglu
Journal:  Pituitary       Date:  2014-06       Impact factor: 4.107

6.  The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas.

Authors:  Chrysanthia A Leontiou; Maria Gueorguiev; Jacqueline van der Spuy; Richard Quinton; Francesca Lolli; Sevda Hassan; Harvinder S Chahal; Susana C Igreja; Suzanne Jordan; Janice Rowe; Marie Stolbrink; Helen C Christian; Jessica Wray; David Bishop-Bailey; Dan M Berney; John A H Wass; Vera Popovic; Antônio Ribeiro-Oliveira; Monica R Gadelha; John P Monson; Scott A Akker; Julian R E Davis; Richard N Clayton; Katsuhiko Yoshimoto; Takeo Iwata; Akira Matsuno; Kuniki Eguchi; Mâdâlina Musat; Daniel Flanagan; Gordon Peters; Graeme B Bolger; J Paul Chapple; Lawrence A Frohman; Ashley B Grossman; Márta Korbonits
Journal:  J Clin Endocrinol Metab       Date:  2008-04-01       Impact factor: 5.958

Review 7.  The clinical, pathological, and genetic features of familial isolated pituitary adenomas.

Authors:  Albert Beckers; Adrian F Daly
Journal:  Eur J Endocrinol       Date:  2007-10       Impact factor: 6.664

Review 8.  Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.

Authors:  Albert Beckers; Lauri A Aaltonen; Adrian F Daly; Auli Karhu
Journal:  Endocr Rev       Date:  2013-01-31       Impact factor: 19.871

9.  Large genomic deletions in AIP in pituitary adenoma predisposition.

Authors:  Marianthi Georgitsi; Elina Heliövaara; Ralf Paschke; Ajith V K Kumar; Marc Tischkowitz; Outi Vierimaa; Pasi Salmela; Timo Sane; Ernesto De Menis; Salvatore Cannavò; Sadi Gündogdu; Anneke Lucassen; Louise Izatt; Simon Aylwin; Gul Bano; Shirley Hodgson; Christian A Koch; Auli Karhu; Lauri A Aaltonen
Journal:  J Clin Endocrinol Metab       Date:  2008-07-15       Impact factor: 5.958

10.  Aryl hydrocarbon receptor-interacting protein and acromegaly.

Authors:  Lauri A Aaltonen
Journal:  Horm Res       Date:  2007-12-10
View more
  4 in total

1.  Germline mutations of aryl hydrocarbon receptor-interacting protein (AIP) gene and somatostatin receptor 1-5 and AIP immunostaining in patients with sporadic acromegaly with poor versus good response to somatostatin analogues.

Authors:  Hande Mefkure Ozkaya; Nil Comunoglu; Muge Sayitoglu; Fatma Ela Keskin; Sinem Firtina; Khusan Khodzhaev; Tugce Apaydin; Nurperi Gazioglu; Necmettin Tanriover; Buge Oz; Pinar Kadioglu
Journal:  Pituitary       Date:  2018-08       Impact factor: 4.107

2.  Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?

Authors:  Sema Ciftci Dogansen; Ozlem Soyluk Selcukbiricik; Seher Tanrikulu; Sema Yarman
Journal:  Pituitary       Date:  2016-06       Impact factor: 4.107

Review 3.  The Role of Single-Nucleotide Polymorphisms in Pituitary Adenomas Tumorigenesis.

Authors:  Sumedh S Shah; Manish K Aghi
Journal:  Cancers (Basel)       Date:  2019-12-09       Impact factor: 6.639

4.  Clinical Relevance of Genetic Analysis in Patients With Pituitary Adenomas: A Systematic Review.

Authors:  Medard F M van den Broek; Bernadette P M van Nesselrooij; Annemarie A Verrijn Stuart; Rachel S van Leeuwaarde; Gerlof D Valk
Journal:  Front Endocrinol (Lausanne)       Date:  2019-12-10       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.